Canagliflozin: A new class of antidiabetic agent targeting the sodium-glucose cotransporter

Cardiology in Review

Volumn 22, Issue 2, 2014, Pages 97-104

  Toderika, Yuliana ^a   Ferguson, Nadia ^a  

^a LONG ISLAND UNIVERSITY   (United States)

Author keywords

canagliflozin; diabetes mellitus; sodiumglucose cotransporter 2 inhibitors

Indexed keywords

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES; TREATMENT OUTCOME;

EID: 84894133232     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0000000000000011     Document Type: Article

References (28)

1. World Health Organization. Diabetes Fact Sheet (number 312). March 2013. Available at: http://www.who.int/mediacentre/factsheets/fs312/en/index.html. Accessed July 29, 2013.
2. Center of Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
3. American Diabetes Association. Diagnosis and classification of diabetes mel-litus. Diabetes Care. 2013;36:S67-S74.
4. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2013;36(suppl 1):S11-S66.
5. Inzucchi SE, Rergenstal RM, Buse JB, et al; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Cam 2012;35:1364-1379.
6. Nathan DM, Holman R, Buse JB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and European Association for the Study of Diabetes. Diabetes Care. 2008:31: 1-11.
7. American Association of Clinical Endocrinologists. A ACE comprehensive diabetes management algorithm. Endocrine Practice. 2013;19:327-336.
8. Song JC, Kaubisch S. Canagliflozin-an emerging treatment option for type 2 diabetes mellitus. Formulary. Available at: http://formularyjournal.mod- ernmedicine.com/formulary-journal/news/user-defined-tags/canagliflozin/ canagliflozin-emerging-treatment-option-type. Accessed September 30, 2013.
9. Clar C, Gill JA, Court R, et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012;2:1-12.
10. Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372-382.
11. Nisly SA, Kolanczyk DM, Walton AM. Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes. Am J Health Syst Pharm. 2013;70:311-319.
12. Canagliflozin [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc.; 2013.
13. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea. Diabetes Care. 2013;36:2508-2515.
14. Rosenstock J, Aggarwal N, Polidori D, et al; Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35:1232-1238.
15. Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36:2154-2161.
16. Devineni D, Curtin CR, Polidori D, et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2013;53:601-610.
17. Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, doubleblind, placebo-controlled, 12-week study. Diabetes Obes Metab. 2013;15:1136-1145.
18. ClinicalTrials.gov, National Institutes of Health. Available at: http://clinicaltri-als.gov. NCT01106690. Accessed July 28, 2013.
19. Wilding JP, Charpentier G, Hollander R et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulfonylurea: a randomised trial. Int J Clin Pract. 2013;67:1267-82.
20. Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type2 diabetes on background metformin monotherapy: A randomised trial. Diabetologia. 2013;56:25 82-92.
21. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463-473.
22. Bode B, Stenlöf K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995). 2013;41:72-84.
23. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941-950.
24. Medication and Herbal Substrates, Inhibitors and Inducers of UGT Enzymes Drug Table. [Pharmacology Weekly web site]. Available at: http://www.phar- macologyweekly.com/content/pages/ugt-enzymes-medications-herbs-sub-strate- inhibitor-inducer. Accessed August 2, 2013. epub August 1, 2013.
25. Wilding JP, Woo Y Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over two years. Diabetes Obes Metab. 2013.
26. Kaku K, Inoue S, Matsuoka O, et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2013;15:432-440.
27. Nainngoan N. FDA Accepts NDA Resubmission of Diabetes Drug Dapagliflozin [Medscape web site]. July 26, 2013. Available at: http://www.medscape.com/ viewarticle/808480. Accessed August 28, 2013.
28. Lowry F: Dapagliflozin Declined by the FDA [Medscape web site]. January 19, 2012. Available at: http://www.medscape.com/viewarticle/757175. Accessed August 28, 2013.